Immunoscore® is our digital pathology and IHC-based immunoassay which provides testing of stage II and III colorectal cancer.
We collaborated with Veracyte, Inc. with respect to the exclusive rights to register and distribute Immunoscore® in China.
Immunoscore® is a fully automated immunoassay and digital image analysis performed on FFPE tissue samples of primary colorectal cancer intended to measure the immune response at the tumor site.
Based on the test results, Immunoscore® provides a chemotherapy treatment strategy recommendation for the patient.
Immunoscore® refines the patient’s risk of occurrence profile and enables physicians to devise treatment plans that maximize clinical benefit while minimizing toxicity.
According to Frost & Sullivan, Immunoscore® is the world’s first standardized immune-based assay for the risk stratification of colorectal cancer and is the first digital immunopathological test used in clinical practice in China.
Its clinical validity and utility are supported by over 15 years of studies and publications, including a global large-scale cohort study conducted by the Society for Immunotherapy of Cancer (the “SITC”).
Immunoscore® provides highly accurate test results and has the ability to predict recurrence risk better than MSI status.
Immunoscore® was included in the ESMO guidelines in 2020 and recommended under NCCN guidelines in 2021 for colorectal cancer as a multigene assay for providing prognostic and predictive information to aid in decisions regarding adjuvant therapy in patients with stage II or III colorectal cancer, and influential studies have been published in the renowned medical journals such as The Lancet.
Immunoscore® obtained CE marking in May 2019.